Journal of Vaccines & Vaccination

Abstract

Evaluation of New Leishmania Major Vaccine Against Immune Responses (Serum’s IL-17 and IL-23 and Spleen White Pulp Changes) Post Challenging with Leishmania Amastigotes in Balb/c Mice

Afshineh Latifynia, Mohammad Javad Gharagozlou, Ahmad Masood, Reza Agha Ebrahimi Samani, Soror Charedar and Mehdi Mohebali

Introduction: Leishmania is a protozoan parasite that has a life cycle in the form of an amastigote (in the mammalian body and in the middle of the macrophage) and promastigote in the mosquito saliva and culture medium with different antigenic determinant sites. Aim: Evaluation of new leishmania major vaccine against serum’s IL-17 and IL-23 and spleen white pulp changes post challenging with leishmania amastigotes survival rate of live mice was also evaluated for the second time after re-exposure. Result: Number of pulp spleen had almost significant differences between doses 100 and 200 μg/ml. LB group had lowest levels of IL-17, IL-23 and mouse weight and highest MPS, PSW/MW , number of pulp spleen and spleen weight was almost significant. LT group had highest levels of IL-23, whether, had lowest levels of mean pulp size, percent of spleen weight/mouse, and spleen weight was almost significant. LBT group had highest levels of IL-17. Lowest levels of IL-23 belonged to LB and control group and highest levels of percent of spleen weight/mouse weight and number of pulp spleen belong to control group also. Conclusion: In LT group, with adjuvant-Teucrium polium, weight of spleen and number of pulp spleen were at lowest level and had highest IL-23. It can be argued that this adjuvant was better than BCG and causes the mice to exhibit stronger immune responses that are likely to go Th1 immune response and protective effect after challenge with live leishmania major.